AT2/Angiotensin Receptor 2/AGTR2 CRISPR/Cas9 KO Plasmid (m): sc-419050

Overview

Agtr2 encodes angiotensin II receptor type 2 (AT2/AGTR2), a seven-transmembrane GPCR within the renin–angiotensin system that modulates cellular responses to angiotensin II. In mouse tissues, AGTR2 signaling is commonly linked to regulation of vascular tone and tissue remodeling and can influence second-messenger pathways including nitric oxide/cGMP signaling, phosphatase activity, and MAPK-dependent programs that shape proliferation, apoptosis, and differentiation. The receptor is studied in endothelial, smooth muscle, neuronal, and renal contexts where it intersects with inflammatory and fibrotic processes and counterbalances AT1-mediated outputs. Dysregulated angiotensin signaling involving AGTR2 has been associated with cardiovascular, renal, and neuroinflammatory disease biology, making it relevant for mechanistic studies of remodeling and stress-response pathways.

AT2/Angiotensin Receptor 2/AGTR2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Agtr2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Agtr2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Agtr2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish AT2/Angiotensin Receptor 2/AGTR2 protein expression.

This CRISPR knockout system enables efficient generation of Agtr2-deficient cell models for investigation of AT2/Angiotensin Receptor 2/AGTR2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

Key Features

• sgRNAs targeting Agtr2 exon(s) critical for AT2/Angiotensin Receptor 2/AGTR2 function
• Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
• GFP reporter for identification of transfected cells
• Pool of plasmids targeting multiple Agtr2 genomic sites to improve knockout efficiency
• Compatible with delivery by transfection

Design Variants

CRISPRs +/- HDRs

• gRNAs encoded by AT2/Angiotensin Receptor 2/AGTR2 CRISPR/Cas9 KO Plasmid (m) and AT2/Angiotensin Receptor 2/AGTR2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Agtr2 locus. One or both targeting designs may be available. See Related Products for availability.
• HDR donor constructs encoded by AT2/Angiotensin Receptor 2/AGTR2 HDR Plasmid (m) and AT2/Angiotensin Receptor 2/AGTR2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Agtr2 homology arms to support homology-directed repair at defined Agtr2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.